|Bid||85.01 x 800|
|Ask||87.83 x 1100|
|Day's Range||85.89 - 88.56|
|52 Week Range||65.63 - 133.74|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.47|
NEW YORK, May 10, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 8) Alcon AG (NYSE: ALC ) BioSig Technologies Inc (NASDAQ: ...
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public offering to sell, subject to market and other conditions, up to $200 million of its common stock. Intercept also announced that it is commencing an underwritten public offering to sell, subject to market and other conditions, up to $200 million aggregate principal amount of convertible senior notes due 2026 (the “Notes”). The Notes will be senior unsecured obligations of Intercept and will mature on May 15, 2026, unless earlier converted, redeemed or repurchased.
The biotech turned in another strong quarterly performance with rising sales for Ocaliva and a regulatory filing for a new indication on the way.
Intercept (ICPT) delivered earnings and revenue surprises of -17.90% and 1.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) announced its latest earnings update in December 2018...
On a per-share basis, the New York-based company said it had a loss of $3.03. The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research ...
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2019. “Our Phase 3 REGENERATE readout demonstrating OCA’s anti-fibrotic benefit in patients with NASH has been a watershed moment for the liver community and underscores our unique competitive opportunity to become the first approved NASH therapy,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.
Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high and has been increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for ICPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ICPT. Sentiment has worsened and traders added to their bearish short positions on April 12. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.74 billion over the last one-month into ETFs that hold ICPT are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results prior to market open on Wednesday, May 8, 2019. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]
A little more than two months after it reported failed results for a late-stage study dubbed STELLAR-4, Gilead said Thursday that another Phase 3 study dubbed STELLAR-3 that evaluated its selonsertib for patients with bridging fibrosis due to NASH did not meet the pre-specified week 48 primary endpoint. The endpoint was for a histologic improvement in fibrosis of more than one stage without worsening of NASH. NASH has no approved drug treatment and therefore offers huge potential for the first mover.